Clinical antidiabetic medication used in Alzheimer’s disease: From basic discovery to therapeutics development

Juan Huang; Juan Huang; Juan Huang; Nanqu Huang; Di Cui; Jingshan Shi; Yu Qiu

doi:10.3389/fnagi.2023.1122300

Frontiers in Aging Neuroscience (Feb 2023)

Clinical antidiabetic medication used in Alzheimer’s disease: From basic discovery to therapeutics development

Juan Huang,
Juan Huang,
Juan Huang,
Nanqu Huang,
Di Cui,
Jingshan Shi,
Yu Qiu

Affiliations

Juan Huang: Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Juan Huang: Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China
Juan Huang: School of Public Health, Zunyi Medical University, Zunyi, Guizhou, China
Nanqu Huang: The Third Affiliated Hospital of Zunyi Medical University (The First People’s Hospital of Zunyi), Zunyi, Guizhou, China
Di Cui: Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China
Jingshan Shi: Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou, China
Yu Qiu: Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

DOI: https://doi.org/10.3389/fnagi.2023.1122300
Journal volume & issue: Vol. 15

Abstract

Read online

Alzheimer’s disease (AD) is a common neurodegenerative disease. Type 2 diabetes mellitus (T2DM) appears to increase and contributing to the risk of AD. Therefore, there is increasing concern about clinical antidiabetic medication used in AD. Most of them show some potential in basic research, but not in clinical research. So we reviewed the opportunities and challenges faced by some antidiabetic medication used in AD from basic to clinical research. Based on existing research progress, this is still the hope of some patients with special types of AD caused by rising blood glucose or/and insulin resistance.

Published in Frontiers in Aging Neuroscience

ISSN: 1663-4365 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://www.frontiersin.org/journals/aging-neuroscience

About the journal

Abstract

Keywords